Thiazolidinedione Monotherapy for T2DM Tied to Lower Dementia Risk
WEDNESDAY, Oct. 12, 2022 -- For patients with type 2 diabetes (T2D), thiazolidinedione (TZD) monotherapy is associated with reduced dementia risk compared with metformin (MET) monotherapy, while sulfonylurea (SU) monotherapy is associated with an... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 12, 2022 Category: Pharmaceuticals Source Type: news

One Type of Older Diabetes Drug Cuts Dementia Risk, Another Ups It One Type of Older Diabetes Drug Cuts Dementia Risk, Another Ups It
Observational study data suggest thiazolidinediones may be protective when it comes to dementia risk in patients with type 2 diabetes, whereas sulfonylureas increase the risk, compared with metformin.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 11, 2022 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

Common diabetes drugs may fight dementia, atrial fibrillation, studies suggest
A class of Type 2 diabetes drugs called glitazones is linked to a 22% reduced risk of dementia, says research led by the University of Arizona. Cleveland Clinic scientists said metformin may treat atrial fibrillation. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 11, 2022 Category: Consumer Health News Source Type: news

Yoga, Mindfulness Could Be Powerful Tools to Manage Blood Sugar
WEDNESDAY, Oct. 5, 2022 -- Yoga, meditation and other mindfulness practices may help people with type 2 diabetes lower their blood sugar — nearly to the degree that standard medications like metformin do, a new analysis suggests. That does not... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2022 Category: General Medicine Source Type: news

SGLT2 Inhibitors, GLP-1 RAs Not Cost-Effective as First-Line T2D Agents
(MedPage Today) -- Although using newer classes of diabetes drugs as first-line therapy can boost life expectancy, this strategy can be quite pricey, according to a cost-effectiveness study. Compared with traditional first-line metformin, first... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 3, 2022 Category: Cardiology Source Type: news

Glucose-Lowering Meds Compared for Use With Metformin in T2DM
MONDAY, Oct. 3, 2022 -- For patients with type 2 diabetes receiving metformin, the addition of glargine and liraglutide is more effective than glimepiride and sitagliptin for achieving and maintaining target glycated hemoglobin levels, while the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 3, 2022 Category: Pharmaceuticals Source Type: news

Unsure on the Best T2D Drug Choice? Let Patients Decide Unsure on the Best T2D Drug Choice? Let Patients Decide
The concept underwent successful testing in a recent trial of 457 patients with type 2 diabetes already on treatment with metformin or metformin plus a sulfonylurea but needed further glycemic control.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - September 26, 2022 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news

GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Effects of Metformin and Lifestyle Interventions on CV Events From the Diabetes Prevention Program and Its Outcome Study Effects of Metformin and Lifestyle Interventions on CV Events From the Diabetes Prevention Program and Its Outcome Study
This review explores study outcomes surrounding the impact of metformin and lifestyle changes in reducing the occurrence of major adverse cardiovascular events in patients with prediabetes.ACC.org (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2022 Category: Cardiology Tags: Cardiology Article Source Type: news

Correction: Utility of support vector machine and decision tree to identify the prognosis of metformin poisoning in the United States: analysis of National Poisoning Data System - Mehrpour O, Saeedi F, Hoyte C, Goss F, Shirazi FM.
Correction: BMC Pharmacol Toxicol 23, 49 (2022) https://doi.org/10.1186/s40360-022-00588-0 Following publication of the original article [1], the authors identified some errors in Figs. 1, 2, 3, 4, 5 and 6. The correct figures are freely available vi... (Source: SafetyLit)
Source: SafetyLit - September 13, 2022 Category: International Medicine & Public Health Tags: Poisoning Source Type: news

Metformin, Testosterone Replacement Linked to Reduced Cancer Risk Metformin, Testosterone Replacement Linked to Reduced Cancer Risk
The use of the diabetes drug and testosterone replacement therapy, independently and in combination, were linked to reductions in the incidence of prostate and colorectal cancers.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 26, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Pricing authority caps rates of key diabetes drugs
India's drug pricing authority has brought two key anti-diabetic drugs - Sitagliptin-Metformin combination and Linagliptin-Metformin combination - under price control. For a 2.5 mg Linagliptin-metformin tablet, the price has been fixed at 16.17, and for the same combination in 5 mg strength, the price will be 25.33 per tablet. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 25, 2022 Category: Pharmaceuticals Source Type: news

Metformin Fails as Early COVID-19 Treatment Metformin Fails as Early COVID-19 Treatment
While cholesterol levels in American adults have improved overall in the past decade, disparities in control have emerged in a new analysis.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 25, 2022 Category: Endocrinology Tags: Infectious Diseases News Source Type: news

Early metformin use may cut Covid hospitalisation, death risk by half: Study
The researchers from the University of Minnesota noted that metformin has been used in the 1950s as an anti-viral called "Fluamine." (Source: The Economic Times)
Source: The Economic Times - August 19, 2022 Category: Consumer Health News Source Type: news

Metformin, Ivermectin, Fluvoxamine Do Not Prevent Severe COVID-19
FRIDAY, Aug. 19, 2022 -- For patients with COVID-19 infection, metformin, ivermectin, and fluvoxamine do not prevent the occurrence of hypoxemia, an emergency department visit, hospitalization, or death, according to a study published in the Aug. 18... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 19, 2022 Category: Pharmaceuticals Source Type: news